Found: 1
Select item for more details and to access through your institution.
Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects.
- Published in:
- Pharmacology Research & Perspectives, 2018, v. 6, n. 1, p. 1, doi. 10.1002/prp2.380
- By:
- Publication type:
- Article